Matthew W McCarthy1, Thomas J Walsh2. 1. Division of General Internal Medicine, Weill Cornell Medical College, New York-Presbyterian Hospital, 525 East 68th Street, Box 331, New York, NY, 10065, USA. mwm9004@med.cornell.edu. 2. Transplantation-Oncology Infectious Diseases Program, Medical Mycology Research Laboratory, Weill Cornell Medical Center, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: Improved management of infectious complications of acute myeloid leukemia (AML) has contributed substantially to the success of care over the past half century. An important approach to reducing infectious complications during the induction period of chemotherapy involves the use of prophylactic antibacterial, antiviral, and antifungal agents targeting likely pathogens. RECENT FINDINGS: There is not a one-size-fits-all approach to prophylaxis; every patient undergoing induction therapy should be evaluated individually and within the context of local microbiologic epidemiology and host risk factors. Pharmacologic and non-pharmacologic interventions as well as novel diagnostic platforms can help mitigate the risk of life-threatening infection in patients with AML who undergo induction chemotherapy.
PURPOSE OF REVIEW: Improved management of infectious complications of acute myeloid leukemia (AML) has contributed substantially to the success of care over the past half century. An important approach to reducing infectious complications during the induction period of chemotherapy involves the use of prophylactic antibacterial, antiviral, and antifungal agents targeting likely pathogens. RECENT FINDINGS: There is not a one-size-fits-all approach to prophylaxis; every patient undergoing induction therapy should be evaluated individually and within the context of local microbiologic epidemiology and host risk factors. Pharmacologic and non-pharmacologic interventions as well as novel diagnostic platforms can help mitigate the risk of life-threatening infection in patients with AML who undergo induction chemotherapy.
Authors: M Tomblyn; T Chiller; H Einsele; R Gress; K Sepkowitz; J Storek; J R Wingard; J-A H Young; M J Boeckh Journal: Bone Marrow Transplant Date: 2009-10 Impact factor: 5.483
Authors: J Palmblad; B Lönnqvist; B Carlsson; G Grimfors; M Järnmark; R Lerner; P Ljungman; C Nyström-Rosander; B Petrini; G Oberg Journal: J Intern Med Date: 1992-04 Impact factor: 8.989
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: Brandon Walker; Margaret V Powers-Fletcher; Robert L Schmidt; Kimberly E Hanson Journal: J Clin Microbiol Date: 2016-01-06 Impact factor: 5.948
Authors: Pinkal M Desai; Janice Brown; Saar Gill; Melham M Solh; Luke P Akard; Jack W Hsu; Celalettin Ustun; Charalambos Andreadis; Olga Frankfurt; James M Foran; John Lister; Gary J Schiller; Matthew J Wieduwilt; John M Pagel; Patrick J Stiff; Delong Liu; Irum Khan; Wendy Stock; Suman Kambhampati; Martin S Tallman; Lawrence Morris; John Edwards; Iskra Pusic; Hagop M Kantarjian; Richard Mamelok; Alicia Wong; Rodney Van Syoc; Lois Kellerman; Swapna Panuganti; Ramkumar Mandalam; Camille N Abboud; Farhad Ravandi Journal: J Clin Oncol Date: 2021-06-22 Impact factor: 50.717